Patents by Inventor Alfons Bosman

Alfons Bosman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunodiagnostic assays using reducing agents
    Patent number: 7935490
    Abstract: The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: May 3, 2011
    Assignee: N.V. Innogenetics
    Inventors: Geert Maertens, Joost Louwagie, Alfons Bosman, Erwin Sablon, Maan Zrein
  • HCV E1 COMPRISING SPECIFIC DISULFIDE BRIDGES
    Publication number: 20080274144
    Abstract: The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins or parts thereof, and to kits comprising said HCV E1 envelope proteins or parts thereof.
    Type: Application
    Filed: March 24, 2008
    Publication date: November 6, 2008
    Applicant: INNOGENETICS N.V
    Inventors: Stany Depraetere, Erik Depla, Gert Verheyden, Alfons Bosman
  • HCV E1 comprising specific disulfide bridges
    Patent number: 7413741
    Abstract: The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins or parts thereof, and to kits comprising said HCV E1 envelope proteins or parts thereof.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: August 19, 2008
    Assignee: Innogenetics N.V.
    Inventors: Stany Depraetere, Erik Depla, Gert Verheyden, Alfons Bosman
  • Particles of HCV envelope proteins: use for vaccination
    Publication number: 20060275323
    Abstract: The present invention is based on the finding that the envelope proteins of HCV induce a beneficial immune response in chronically HCV-infected chimpanzees. The immunization can preferentially be carried out using HCV envelope proteins in the form of particles which are produced in a detergent-assisted manner. The envelope proteins when presented as such to chronic HCV carriers are highly immunogenic and stimulate both the cellular and humoral immune response.
    Type: Application
    Filed: June 2, 2006
    Publication date: December 7, 2006
    Applicant: INNOGENETICS N.V.
    Inventors: Erik Depla, Geert Maertens, Alfons Bosman, Frans Van Wijnendaele
  • Immunodiagnostic assays using reducing agents
    Publication number: 20060263854
    Abstract: The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent.
    Type: Application
    Filed: August 2, 2006
    Publication date: November 23, 2006
    Applicant: N.V. INNOGENETICS
    Inventors: Geert Maertens, Joost Louwagie, Alfons Bosman, Erwin Sablon, Maan Zrein
  • HCV E1 comprising specific disulfide bridges
    Publication number: 20060034861
    Abstract: The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins or parts thereof, and to kits comprising said HCV E1 envelope proteins or parts thereof.
    Type: Application
    Filed: March 8, 2005
    Publication date: February 16, 2006
    Applicant: INNOGENETICS N.V
    Inventors: Stany Depraetere, Erik Depla, Gert Verheyden, Alfons Bosman
  • Redox reversible HCV proteins with native-like conformation
    Publication number: 20040185061
    Abstract: The present invention relates to HCV proteins in which cysteine residues are reversibly protected during purification. Eventually, this purification procedure results in HCV proteins with biological activity and a native-like protein conformation, which present corresponding epitopes. The present invention pertains also to drug screening methods using these HCV proteins, and diagnostic and therapeutic applications, such as vaccines and drugs.
    Type: Application
    Filed: April 16, 2004
    Publication date: September 23, 2004
    Applicant: Innogenetics N.V.
    Inventors: Alfons Bosman, Erik Depla, Geert Maertens
  • Particles of HCV envelope proteins: use for vaccination
    Publication number: 20030202987
    Abstract: The present invention is based on the finding that the envelope proteins of HCV induce a beneficial immune response in chronically HCV-infected chimpanzees. The immunization can preferentially be carried out using HCV envelope proteins in the form of particles which are produced in a detergent-assisted manner. The envelope proteins when presented as such to chronic HCV carriers are highly immunogenic and stimulate both the cellular and humoral immune response.
    Type: Application
    Filed: April 16, 2003
    Publication date: October 30, 2003
    Applicant: INNOGENETICS
    Inventors: Erik Depla, Geert Maertens, Alfons Bosman, Frans Van Wijnendaele
  • Particles of HCV envelope proteins: use for vaccination
    Patent number: 6635257
    Abstract: The present invention is based on the finding that the envelope proteins of HCV induce a beneficial immune response in chronically HCV-infected chimpanzees. The immunization can preferentially be carried out using HCV envelope proteins in the form of particles which are produced in a detergent-assisted manner. The envelope proteins when presented as such to chronic HCV carriers are highly immunogenic and stimulate both the cellular and humoral immune response.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: October 21, 2003
    Assignee: Innogentics N.V.
    Inventors: Erik Depla, Geert Maertens, Alfons Bosman, Frans Van Wijnendaele